Rationale for Applying Spirocyclic Building Blocks in Drug Molecule Optimization: Three-Dimensionalization, Conformational Control, and Property Trade-offs

1 Why Drug Molecules May Consider Introducing Spirocycles

1.1 Why Spirocycles Have Become Important Scaffolds in Drug Molecule Optimization

In the early stages of drug discovery, researchers usually focus first on activity: whether a compound can bind to the target, inhibit enzymatic activity, or produce the desired effect at the cellular level. However, as a project enters lead optimization, the factors that limit further progression are often not limited to activity alone, but rather involve the overall property profile of the molecule.

Common issues include insufficient solubility, excessive lipophilicity, overly strong basicity, poor selectivity, inadequate metabolic stability, and increased safety risks. Among lead compounds, nitrogen-containing saturated rings, planar aromatic structures, and flexible linkers are frequently encountered. Although these motifs can facilitate rapid exploration of structure–activity relationships (SAR), they may also introduce property burdens during later-stage optimization.

Spirocyclic scaffolds have attracted attention precisely because they can simultaneously alter a molecule’s three-dimensional shape, conformational freedom, and physicochemical properties. In drug design, spirocyclic scaffolds are often used to make the spatial orientation, binding mode, and property modulation of molecules more controllable.

Optimization challenge	Impact on drug development	Potential role of spirocycles
Strong molecular planarity	May affect solubility, selectivity, and drug-like properties	Increase three-dimensionality and reduce dependence on planar structures
Excessive conformational flexibility	Reduces the proportion of bioactive binding conformations	Restrict free rotation and fix the orientation of key pharmacophores
High lipophilicity or basicity	May increase off-target effects and hERG risk	Modulate LogD and pKa through heterospirocycles
Suboptimal linker direction	Pharmacophores may not align well with the target pocket	Alter the spatial projection direction of substituents
Insufficient metabolic or configurational stability	Affects in vivo exposure and pharmacokinetic properties	Replace unstable motifs and improve structural stability

1.2 Basic Structure of Spirocycles

A spirocyclic scaffold is a molecular structure in which two or more rings share a single atom. This shared atom is called the spiro atom. Unlike fused rings, in which two rings share a bond, spirocycles share only one atom between two rings; therefore, the two rings often extend in a distinctly non-coplanar manner.

 

This structural feature leads to three major effects:

Structural feature of spirocycles	Impact on drug design
Two rings extend in a non-coplanar manner	Increases molecular three-dimensionality
The spiro atom locks the relative spatial arrangement of the two ring systems	Reduces accessible conformations and restricts changes in substituent exit vectors
Substituents project in different directions	Alters the spatial orientation of pharmacophores

1.3 Spirocycles Represent a Shift from Planar Modification to Three-Dimensional Control

In traditional lead optimization, aromatic rings, piperidine, piperazine, and flexible linkers are frequently used because they are synthetically convenient and allow efficient SAR progression. However, as molecules become larger, more planar, and more lipophilic, simply adding substituents within a two-dimensional plane often makes it difficult to improve activity, selectivity, and absorption, distribution, metabolism, excretion and toxicity (ADME-Tox) properties at the same time.

The value of spirocycles lies in the fact that they do not simply extend an existing planar structure, but instead guide the molecule into new three-dimensional space. By connecting two ring systems through a spiro atom, spirocycles allow substituents to project in different directions, thereby changing how the molecule interacts with the target pocket, solvent environment, and metabolic enzymes.

2 Representative Cases: What Specific Problems Can Spirocycles Address?

2.1 PLK4: Replacing a Configurationally Unstable Motif to Improve Pharmacokinetic Properties

Polo-like kinase 4 (PLK4) is an important regulatory kinase involved in centriole duplication. During the optimization of PLK4 inhibitors, early studies found that although alkene-linked structures could provide activity, they had limitations in terms of configurational stability and pharmacokinetic properties.

Based on an early alkene-linked series, researchers introduced a spirocyclopropyl structure to obtain a series of spiro[cyclopropane-1,3′-indolin]-2′-one compounds. This type of spirocyclopropyl structure can serve as a conformationally restricted replacement for an alkene linker. While maintaining affinity for PLK4 and antiproliferative activity, it improves physicochemical properties, in vitro ADME, and pharmacokinetic properties.

2.2 Pks13: Replacing Nitrogen-Containing Rings to Reduce hERG-Related Risk

Polyketide synthase 13 (Pks13) is a key target in the biosynthesis of mycolic acids in Mycobacterium tuberculosis. During optimization of the TAM16 series of Pks13 inhibitors, early lead compounds showed a risk of inhibiting the human ether-à-go-go-related gene (hERG) potassium channel. Researchers introduced 2-oxa-6-azaspiro[3.4]octane at the P3 position to improve the hERG-related properties of this compound series.

Piperidine is a six-membered saturated nitrogen-containing heterocycle. Its SMILES can be represented as N1CCCCC1 or C1CCNCC1. It is commonly used to improve aqueous solubility and salt-forming ability, but in some molecules it may increase basicity, contribute to lipophilicity, and raise hERG risk.

2-Oxa-6-azaspiro[3.4]octane consists of an oxygen-containing four-membered ring and a nitrogen-containing five-membered ring that share one spiro atom. Its SMILES can be represented as C1C2(CCNC2)CO1 or C1CNCC12COC2. The oxygen atom can increase polarity, while the nitrogen atom retains a protonatable site. Therefore, this scaffold can be used to modulate the properties of certain nitrogen-containing ring fragments.

 

2.3 PARP-1: Replacing Piperazine to Modulate Selectivity and Cytotoxicity

Poly(ADP-ribose) polymerase 1 (PARP-1) is involved in DNA damage recognition and repair. PARP inhibitors such as olaparib have important value in cancer therapy, but the DNA damage induction and cytotoxicity associated with PARP inhibition also limit their use in certain non-oncology diseases.

For non-oncology indications, an ideal PARP-1 inhibitor would often be expected to retain PARP-1 inhibitory activity while reducing DNA damage induction and cytotoxicity. Within the olaparib framework, researchers used a diazaspirocyclic structure to replace the piperazine fragment. The resulting compounds showed high affinity for PARP-1, while DNA damage induction and cytotoxicity were reduced.

Piperazine is a six-membered saturated diazacycle with the SMILES N1CCNCC1. The two nitrogen atoms are located at the 1,4-positions. Piperazine is commonly used as a linker to modulate solubility and salt-forming ability, but in some molecules it may also introduce issues related to basicity, metabolism, and off-target effects.

2.4 PfHDAC1: Optimizing Linker Direction to Improve Safety

Plasmodium falciparum histone deacetylase 1 (PfHDAC1) is a potential target in antimalarial drug discovery. The histone deacetylase (HDAC) inhibitor quisinostat has antimalarial activity, but its cytotoxicity limits further application.

Researchers designed and synthesized a series of spirocyclic hydroxamic acid derivatives based on quisinostat to improve antimalarial activity and safety. Related studies showed that some spirocyclic derivatives exhibited multistage antimalarial activity and improved cytotoxicity and pharmacokinetic properties; PfHDAC1 was confirmed as an important target for the active compounds in this series. In this type of optimization, spirocycles modulate the balance between antimalarial activity and cytotoxicity by changing the spatial relationship between pharmacophores.

2.5 Common Patterns Across the Four Cases

Case	Original problem	Role of the spirocycle	Core value
PLK4	Alkene configurational instability and PK properties requiring improvement	Spirocyclopropyl replacement of the alkene	Improves structural stability and pharmacokinetic performance
Pks13	hERG risk; basicity and lipophilicity requiring modulation	Heterospirocyclic replacement of a nitrogen-containing ring fragment	Reduces off-target and physicochemical risks
PARP-1	Need to reduce DNA damage and cytotoxicity	Diazaspirocyclic replacement of piperazine	Modulates selectivity and toxicity
PfHDAC1	Activity and cytotoxicity requiring rebalancing	Spirocyclic linker modulates spatial orientation	Improves the activity–safety relationship

3 Advantages and Costs Under the Same Structural Mechanism

3.1 Increased Three-Dimensionality: Beneficial for Selectivity, but More Demanding for Pocket Fit

Spirocycles make molecules more three-dimensional, which can help improve spatial complementarity and reduce certain nonspecific interactions. However, increased three-dimensionality also means that the molecule becomes more demanding in terms of the shape of the binding pocket. If the substituent directions provided by the spirocycle match the target pocket, potency and selectivity may improve; if they do not match, the molecule may lack the ability to re-adapt through free rotation, and the hit rate may instead decrease.

3.2 Increased Conformational Restriction: Improves the Proportion of Bioactive Conformations, but Reduces Molecular Adaptability

The rigidity of spirocycles can increase the proportion of bioactive binding conformations and reduce interference from nonproductive conformations. However, the same rigidity also reduces the molecule’s ability to adapt to different binding modes. Therefore, spirocycles are more suitable for projects with an existing activity basis, preliminary SAR, or structural biology information. For early-stage screening where the target binding mode is not yet clear, excessive reliance on highly rigid spirocyclic scaffolds may reduce exploration efficiency.

3.3 Small Spirocyclic Heterocycles Can Modulate ADME-Tox-Related Properties, but May Also Introduce Stability Risks

Small spirocyclic heterocycles such as azaspirocycles, oxaspirocycles, and spiro-oxetane-containing scaffolds are commonly used to modulate basicity, lipophilicity, solubility, and metabolic stability. Their potential advantages come from a defined three-dimensional shape, higher Fsp³, and the ability to tune properties through heteroatoms. However, the direction of improvement depends on the specific core scaffold, substituents, and target environment. These structures may also introduce new issues:

Potential issue	Impact
Higher ring strain	May affect chemical stability
Unusual heteroatom arrangement	May alter pKa and metabolic pathways
Higher reactivity of small rings	May lead to ring opening or unexpected reactions
Unclear metabolite profile	May introduce new safety risks
Complex synthetic route	May affect scale-up preparation and cost control

3.4 Synthetic Accessibility Does Not Equal Developability

In the early stages of drug discovery, milligram-scale quantities of building blocks are sufficient for SAR exploration. However, after entering candidate compound selection and preclinical development, spirocyclic structures must meet much stricter requirements.

Key factors to evaluate include whether the synthetic route is concise; whether raw materials are stable and readily available; whether key intermediates are stable; whether stereoisomers can be controlled; whether the scale-up process is safe; whether the impurity profile is acceptable; and whether the cost can support subsequent development. For a drug discovery project, structural novelty is only the starting point. Stability, availability, and scalability ultimately determine whether a structure is truly usable.

4 How to Decide Whether to Introduce a Spirocycle in a Project

4.1 Identify the Problem Before Selecting the Structure

The project problem should first be clearly defined. Then, one should determine whether the problem is related to three-dimensional shape, conformation, basicity, lipophilicity, off-target effects, or metabolic stability. Finally, an appropriate spirocyclic scaffold should be selected for validation.

Decision step	Key question
Define the project problem	Is the current limitation activity, selectivity, ADME-Tox, or synthetic feasibility?
Identify the structural cause	Is the problem related to planarity, conformation, basicity, lipophilicity, or linker direction?
Select a spirocyclic scaffold	Is three-dimensionalization, conformational restriction, or heteroatom-based modulation needed?
Experimental validation	Does it truly improve SAR, ADME-Tox, stability, and safety?

If the current main problem in a project is insufficient target activity and the binding mode is still unclear, blindly introducing a rigid spirocycle may reduce exploration efficiency. In contrast, if a project already has a clear activity basis but is limited by selectivity, hERG risk, metabolic stability, exposure, or linker orientation, spirocycles are more likely to provide value.

The effect of spirocyclic replacement depends on the core scaffold, substituent exit vectors, the shape of the target pocket, changes in pKa/LogD, migration of metabolic soft spots, and synthetic scalability. The same spirocyclic building block may produce different or even opposite SAR and ADME-Tox outcomes in different projects. Therefore, validation through parallel comparator compounds and measured experimental data is still required.

4.2 Situations Where Spirocycles May Be Prioritized

Project problem	Potential role of spirocycles
Strong molecular planarity	Increase three-dimensionality and structural differentiation
Conformational dispersion caused by flexible linkers	Fix pharmacophore orientation and increase the proportion of bioactive conformations
Basicity and lipophilicity issues caused by piperidine or piperazine fragments	Use heterospirocycles to modulate pKa, LogD, and off-target risk
hERG inhibition risk	In some molecules, risk may be reduced by lowering basicity and lipophilicity
Insufficient selectivity between the target and homologous proteins	Alter spatial orientation and enhance recognition differences between targets
Configurational or metabolic instability in the original structure	Improve structural stability through spirocyclic replacement
Project already has preliminary SAR	Conduct targeted optimization based on clearly defined problems

4.3 Situations Where Spirocycles Should Not Be Introduced Blindly

Situation	Reason
Target binding mode is not yet clear	Rigid structures may reduce early-stage exploration efficiency
The current problem is not related to conformation, three-dimensionality, or ADME-Tox	Spirocyclic replacement may not address the main issue
The spirocycle significantly increases synthetic difficulty	May slow SAR progression and subsequent scale-up
The intended scaffold has insufficient stability	May introduce new chemical and metabolic risks
Stereoisomers are difficult to prepare or characterize	May affect efficacy, safety, and quality control
The source of property improvement after replacement is unclear	Makes it difficult to guide subsequent structural optimization

5 Classification Table of Representative Chemicals Related to Spirocyclic Building Blocks

Table 1 Conventional Heterocyclic Reference Compounds and Basic Carbospirocyclic Building Blocks

Category	CAS No.	Aladdin Cat. No.	Name	Specification or Purity	Product Features and Applications
Six-membered oxaza-heterocycle reference compound	110-91-8	M109058	Morpholine	Distillation grade, ≥99.5%	A six-membered oxygen- and nitrogen-containing ring. It can be used to compare differences in polarity, basicity, solubility, and conformation before and after replacement with oxaza-spirocyclic scaffolds.
Six-membered diaza-heterocycle reference compound	110-85-0	P755827	Piperazine	UltraBio™, anhydrous grade, ≥99% (T)	A six-membered diaza ring linker. It can be used in studies of diazaspirocyclic replacement, three-dimensionalization of linkers, and modulation of cytotoxicity.
Six-membered aza-heterocycle reference compound	110-89-4	P1506301	Piperidine (controlled precursor chemical)	AR, ≥99.5%	A six-membered nitrogen-containing ring. It can be used to compare changes in basicity, lipophilicity, and cardiac potassium channel risk before and after replacement of piperidine with azaspirocyclic or oxaza-spirocyclic scaffolds.
Four-membered aza small-ring building block	36520-39-5	A103569	Azetidine hydrochloride	≥97%	A basic four-membered nitrogen-containing small-ring unit. It can be used for constructing azaspirocyclic scaffolds, studying small-ring strain effects, and designing nitrogen-containing three-dimensional fragments.
Carbospirocyclic ketone building block	30152-57-9	S176051	Spiro[3.3]heptan-2-one	≥97%	A ketone-containing carbospirocyclic scaffold. It can be used for carbonyl derivatization, introduction of three-dimensional saturated scaffolds, and construction of rigid linker units.
Carbospirocyclic alcohol building block	1502422-51-6	S174361	Spiro[3.3]heptan-2-ol	≥97%	An alcohol-containing carbospirocyclic intermediate. It can be used for etherification, esterification, oxidative transformations, and preparation of oxygen-containing three-dimensional fragments.
Carbospirocyclic carboxylic acid building block	28114-87-6	S175996	Spiro[3.3]heptane-2-carboxylic acid	≥97%	A carboxylic acid-type carbospirocyclic building block. It can be used for amidation, esterification, and introduction of rigid acidic fragments.
Carbonyl carboxylic acid carbospirocyclic building block	889944-57-4	O178034	6-Oxospiro[3.3]heptane-2-carboxylic acid	≥97%	Contains both carboxylic acid and carbonyl reactive sites. It can be used for amidation, reductive amination, carbonyl modification, and design of multidirectional spirocyclic derivatives.
Dicarbonyl carbospirocyclic building block	20061-23-8	S631370	Spiro[3.3]heptane-2,6-dione	≥97%	A diketone-type carbospirocyclic scaffold. It can be used for amination, reduction, carbonyl transformation, and construction of symmetric three-dimensional scaffolds.

Table 2 Aza-, Diaza-, and Oxaza-Spirocyclic Core Scaffolds

Category	CAS No.	Aladdin Cat. No.	Name	Specification or Purity	Product Features and Applications
Oxaza[3.4] spirocyclic salt core scaffold	1359656-12-4	O1017899	6-Oxa-2-azaspiro[3.4]octane hydrochloride	≥98%	An oxaza[3.4] spirocyclic salt core scaffold. It can be used for nitrogen-containing ring replacement, studies of heteroatom positional effects, and design of basicity-modulating fragments.
Aza[3.3] spirocyclic salt core scaffold	1986337-29-4	A679103	1-Azaspiro[3.3]heptane hydrochloride	≥97%	A small aza[3.3] spirocyclic salt core scaffold. It can be used for compressed piperidine replacement, exploration of three-dimensional nitrogen-containing scaffolds, and conformational restriction studies.
Diaza[3.3] spirocyclic salt core scaffold	1184963-68-5	D637445	2,6-Diazaspiro[3.3]heptane dihydrochloride	≥97%	A diaza[3.3] spirocyclic core scaffold. It can be used for bioisosteric replacement of piperazine, three-dimensionalization of diaza linkers, and modulation of polar fragments.
Oxaza[3.3] spirocyclic free-base core scaffold	174-78-7	O174980	2-Oxa-6-azaspiro[3.3]heptane	≥97%	A small oxaza[3.3] spirocyclic free base. It can be used for screening heteroatom combinations, ring-size variations, and three-dimensional polar fragments.
Aza[3.3] spirocyclic salt core scaffold	1420271-08-4	A729841	2-Azaspiro[3.3]heptane hydrochloride	≥97%	An aza[3.3] spirocyclic salt core scaffold. It can be used for screening small nitrogen-containing spirocyclic fragments, modulating basic fragments, and designing conformationally restricted structures.
Aza[3.4] spirocyclic free-base core scaffold	665-41-8	A682721	2-Azaspiro[3.4]octane	≥97%	An aza[3.4] spirocyclic free base. It can be used for nitrogen-containing ring replacement, modulation of substituent exit vectors, and construction of three-dimensional amine fragments.
Aza[3.4] spirocyclic salt core scaffold	1414885-18-9	A999318	6-Azaspiro[3.4]octane hydrochloride	≥95%	A positional isomeric aza[3.4] spirocyclic salt core scaffold. It can be used to compare the effects of nitrogen atom position on salt-forming ability, conformation, and binding direction.
Oxaza[3.3] spirocyclic oxalate core scaffold	1380571-72-1	O173778	6-Oxa-1-azaspiro[3.3]heptane hemioxalate	≥95%	An oxaza[3.3] spirocyclic oxalate. It can be used for compressed morpholine replacement, studies of heteroatom effects in small spirocycles, and construction of polar scaffolds.

Table 3 Protected and Derivatizable Spirocyclic Building Blocks

Category	CAS No.	Aladdin Cat. No.	Name	Specification or Purity	Product Features and Applications
Ketone-containing protected aza[3.3] spirocyclic building block	1181816-12-5	T586510	tert-Butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate	≥98%	A Boc-protected ketone-containing aza[3.3] spirocycle. It can be used for reductive amination, oxime formation, carbonyl derivatization, and construction of three-dimensional amine fragments.
Ketone-containing protected aza[3.4] spirocyclic building block	203661-71-6	T175577	tert-Butyl 2-oxo-6-azaspiro[3.4]octane-6-carboxylate	≥97%	A Boc-protected oxo-aza[3.4] spirocycle. It can be used for carbonyl transformation, amine derivatization, reductive amination, and construction of [3.4] spirocyclic series.
Protected oxaza[3.4] spirocyclic building block	1245816-31-2	B166689	6-Boc-2-oxa-6-azaspiro[3.4]octane	≥97%	A Boc-protected oxaza[3.4] spirocycle. It can be used for introducing oxygen- and nitrogen-containing spirocycles, fragment coupling under nitrogen protection, and preparation of amine derivatives after deprotection.
Ketone-containing protected aza[3.4] spirocyclic building block	1363382-39-1	T173660	tert-Butyl 6-oxo-2-azaspiro[3.4]octane-2-carboxylate	≥97%	A [3.4] octane ketone-containing azaspirocyclic building block. It can be used for reductive amination, carbonyl modification, preparation of conformationally restricted fragments, and exploration of substituent exit vectors.
Amino-containing protected aza[3.3] spirocyclic building block	1211586-09-2	T172620	tert-Butyl 6-amino-2-azaspiro[3.3]heptane-2-carboxylate	≥97%	A difunctional spirocyclic building block containing an amino group and a protected amine. It can be used for amidation, urea formation, sulfonylation, and expansion of three-dimensional amine fragments.
Hydroxy-containing protected aza[3.3] spirocyclic building block	1147557-97-8	T172151	tert-Butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate	≥97%	A hydroxy-functionalized azaspirocyclic building block. It can be used for esterification, etherification, oxidative transformations, and modulation of polar fragments.
Formyl-containing protected aza[3.3] spirocyclic building block	1440960-67-7	T174245	tert-Butyl 6-formyl-2-azaspiro[3.3]heptane-2-carboxylate	≥97%	A formyl-containing azaspirocyclic building block. It can be used for reductive amination, olefination reactions, heterocycle merging, and extension of three-dimensional fragments.
Monoprotected diaza[3.3] spirocyclic building block	1041026-70-3	T405203	tert-Butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate	≥90%	A monoprotected diaza[3.3] spirocyclic building block that retains one modifiable nitrogen site. It can be used for stepwise functionalization, construction of piperazine-replacement series, and optimization of diaza linkers.
Protected oxaza[3.3] spirocyclic building block	1223573-41-8	O166592	tert-Butyl 1-oxa-6-azaspiro[3.3]heptane-6-carboxylate	—	A Boc-protected oxaza[3.3] spirocycle. It can be used for fragment coupling under nitrogen protection, preparation of amine derivatives after deprotection, and morpholine replacement studies.

Note: The above products are representative Aladdin products for scientific research and formulation research. For more information on product specifications, grades, and COA documents, please search by “product name/CAS/catalog number” on the Aladdin official website.

For more related articles, please see below:

Spirocyclic Building Blocks for Scaffold Assembly

Innovations in the design of stereospecific drug molecular structures: Spirocyclic Scaffolds

Cyclic isomers--Azabicyclic molecular building blocks to aid drug design

One Atom Can Change a Drug’s Fate: Atom-Level Knobs and a Functional-Group Toolbox for Medicinal Chemistry (Methyl / Halogen Bonding / 3D Building Blocks / Late-Stage Fluorination + Product-Selection Tables)

The Role of 7-Membered Nitrogen Heterocycles in Drug Discovery: Microstate Management, Conformational Bias, and Developability Trade-offs (with Research Selection Navigator and Product Tables 1–3)

Pyridinones as “Property Knobs” in Drug Design: From Tautomers and H-Bonding Fingerprints to Product Selection (Tables A–C)